Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

EQRX | EQRx Inc

Index	RUT	P/E	-	EPS (ttm)	-0.55	Insider Own	38.42%	Shs Outstand	478.67M	Perf Week	0.23%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-0.67	Insider Trans	0.00%	Shs Float	300.12M	Perf Month	-4.11%
Income	-262.78M	PEG	-	EPS next Q	-0.16	Inst Own	40.72%	Short Float / Ratio	4.42% / 2.89	Perf Quarter	14.18%
Sales	0.00M	P/S	-	EPS this Y	-88.89%	Inst Trans	20.57%	Short Interest	13.27M	Perf Half Y	13.01%
Book/sh	2.58	P/B	0.86	EPS next Y	1.47%	ROA	-18.00%	Target Price	-	Perf Year	-55.25%
Cash/sh	2.59	P/C	0.86	EPS next 5Y	-	ROE	-19.30%	52W Range	1.58 - 5.70	Perf YTD	-9.96%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-21.05%	52W High	-61.17%	Beta	0.49
Dividend %	-	Quick Ratio	22.60	Sales past 5Y	0.00%	Gross Margin	-	52W Low	40.19%	ATR	0.06
Employees	362	Current Ratio	22.60	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	46.48	Volatility	2.17% 2.60%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	13.30%	Profit Margin	-	Rel Volume	0.77	Prev Close	2.21
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	4.60M	Price	2.21
Recom	-	SMA20	-1.73%	SMA50	1.33%	SMA200	6.48%	Volume	885,611	Change	0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight
Nov-11-22	Downgrade	Jefferies	Buy → Hold	$5.60 → $3.20
Nov-11-22	Downgrade	Goldman	Buy → Neutral	$8 → $5
Aug-16-22	Initiated	JP Morgan	Neutral	$5.50
Jun-13-22	Initiated	Goldman	Buy	$8
Apr-22-22	Initiated	Cowen	Outperform
Mar-18-22	Initiated	Jefferies	Buy	$5.60

Aug-01-23 07:00AM	Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital (GlobeNewswire) +18.13%
May-08-23 04:01PM	EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 08:00AM	EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023 (GlobeNewswire)
Feb-23-23 07:00AM	EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress (GlobeNewswire)
Jan-03-23 08:00AM	EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Dec-19-22 08:00AM	EQRx Announces Acceptance of Marketing Authorization Application by the UKs Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer (GlobeNewswire)
Dec-02-22 08:00AM	EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer (GlobeNewswire) +7.69%
Nov-10-22 07:00AM	EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results (GlobeNewswire) -28.62%
Nov-07-22 08:00AM	EQRx to Participate in the Jefferies 2022 London Healthcare Conference (GlobeNewswire)
Oct-28-22 08:00AM	EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 (GlobeNewswire)
Aug-11-22 07:00AM	EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress (GlobeNewswire) -21.20%
Aug-07-22 04:10AM	EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer (GlobeNewswire)
Jul-28-22 08:00AM	EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 (GlobeNewswire)
Jul-03-22 08:22AM	Companies Like EQRx (NASDAQ:EQRX) Are In A Position To Invest In Growth (Simply Wall St.)
Jun-14-22 07:00AM	EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer (GlobeNewswire)
08:00AM	Loading…
May-31-22 08:00AM	EQRx to Participate at Upcoming Investor Conferences (GlobeNewswire) +7.34%
May-26-22 05:00PM	EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022 (GlobeNewswire)
May-13-22 07:00AM	EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress (GlobeNewswire) +24.17%
Apr-29-22 08:00AM	EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022 (GlobeNewswire)
Apr-27-22 10:30AM	EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting (GlobeNewswire)
Mar-24-22 11:39AM	What Type Of Shareholders Own The Most Number of EQRx, Inc. (NASDAQ:EQRX) Shares? (Simply Wall St.) +6.15%
Mar-23-22 07:00AM	EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress (GlobeNewswire)
Mar-09-22 08:00AM	EQRx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Wednesday, March 23, 2022 (GlobeNewswire) +5.42%
Mar-02-22 08:00AM	EQRx to Participate in Cowens 42nd Annual Health Care Conference (GlobeNewswire)
Jan-18-22 07:00PM	Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer (GlobeNewswire)
08:00AM	EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer (GlobeNewswire)
Jan-10-22 07:30AM	EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines (GlobeNewswire)
Jan-07-22 08:00AM	EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower Costs (GlobeNewswire)
Jan-03-22 08:00AM	EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-21 06:35AM	We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth (Simply Wall St.)

EQRx, Inc. is a pharmaceutical company, which engages in developing and delivering innovative medicines to patients having chronic conditions. The company was founded by Alexis A. Borisy, Sandra J. Horning, Robert M. Forrester, Peter Bach, and Melanie I. Nallicheri on August 26, 2019 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EQRX | EQRx Inc

Upgrade your FINVIZ experience